This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mulato, A. S.
Right arrow Articles by Cherrington, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mulato, A. S.
Right arrow Articles by Cherrington, J. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 1998, p. 1620-1628, Vol. 42, No. 7
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from AIDS Patients after Prolonged Adefovir Dipivoxil Therapy

A. S. Mulato, P. D. Lamy, M. D. Miller, W.-X. Li, K. E. Anton, N. S. Hellmann, and J. M. Cherrington*

Gilead Sciences, Inc., Foster City, California 94404

Received 30 September 1997/Returned for modification 15 December 1997/Accepted 16 April 1998

Adefovir dipivoxil [bis(pivaloyloxymethyl)-ester prodrug], an orally bioavailable prodrug of adefovir [9-(2-phosphonylmethoxyethyl)adenine], is currently in phase III clinical trials for the treatment of human immunodeficiency virus (HIV). In vitro experiments demonstrated that either a K65R or a K70E mutation in HIV reverse transcriptase (RT) was selected in the presence of adefovir, conferring a 16- or 9-fold decrease in susceptibility to adefovir, respectively. Previous data demonstrated that patients receiving adefovir dipivoxil monotherapy (125 mg daily) for 12 weeks experienced a median decrease in HIV RNA levels of 0.5 log10 copies/ml and that resistance to adefovir dipivoxil did not arise during that period. In the present investigation, a further study was undertaken to investigate whether RT mutations developed among viruses from patients who completed the 12-week study and who opted to enroll in a maintenance phase of prolonged (6- to 12-month) adefovir dipivoxil therapy (120 mg daily). Concomitant treatment with antiretroviral agents was permitted during the maintenance phase. The median decreases in HIV RNA levels for patients who completed 6 or 12 months of maintenance-phase dosing were 0.6 and 1.14 log10 copies/ml, respectively. The reductions in the HIV RNA levels were similar among patients who received adefovir dipivoxil with or without concomitant treatment with antiretroviral agents. Viruses from 8 of 29 patients dosed for up to 12 months developed RT mutations that were not present at baseline; these mutations may have been related to adefovir dipivoxil therapy. Viruses from two of the eight patients developed the K70E mutation while the patients were on therapy, but none of the viruses from patients developed the K65R RT substitution. Despite the development of RT mutations, sustained reductions (6 to 12 months) in viral load (>= 0.7 log10 copies/ml decrease from baseline) were observed in all eight patients.

* Corresponding author. Mailing address: Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, CA 94404. Phone: (650) 573-4837. Fax: (650) 573-4890. E-mail: julie_cherrington{at}gilead.com.

Antimicrobial Agents and Chemotherapy, July 1998, p. 1620-1628, Vol. 42, No. 7
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Bradshaw, D., Malik, S., Booth, C., Van Houtte, M., Pattery, T., Waters, A., Ainsworth, J., Geretti, A. M. (2007). Novel Drug Resistance Pattern Associated with the Mutations K70G and M184V in Human Immunodeficiency Virus Type 1 Reverse Transcriptase. Antimicrob. Agents Chemother. 51: 4489-4491 [Abstract] [Full Text]  
  • Sluis-Cremer, N., Sheen, C.-W., Zelina, S., Torres, P. S. A., Parikh, U. M., Mellors, J. W. (2007). Molecular Mechanism by Which the K70E Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Resistance to Nucleoside Reverse Transcriptase Inhibitors. Antimicrob. Agents Chemother. 51: 48-53 [Abstract] [Full Text]  
  • Delaugerre, C., Marcelin, A.-G., Thibault, V., Peytavin, G., Bombled, T., Bochet, M.-V., Katlama, C., Benhamou, Y., Calvez, V. (2002). Human Immunodeficiency Virus (HIV) Type 1 Reverse Transcriptase Resistance Mutations in Hepatitis B Virus (HBV)-HIV-Coinfected Patients Treated for HBV Chronic Infection Once Daily with 10 Milligrams of Adefovir Dipivoxil Combined with Lamivudine. Antimicrob. Agents Chemother. 46: 1586-1588 [Abstract] [Full Text]  
  • van Rompay, K. K. A., Cherrington, J. M., Marthas, M. L., Lamy, P. D., Dailey, P. J., Canfield, D. R., Tarara, R. P., Bischofberger, N., Pedersen, N. C. (1999). 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) Therapy Prolongs Survival of Infant Macaques Inoculated with Simian Immunodeficiency Virus with Reduced Susceptibility to PMPA. Antimicrob. Agents Chemother. 43: 802-812 [Abstract] [Full Text]  
  • van Rompay, K. K. A., Dailey, P. J., Tarara, R. P., Canfield, D. R., Aguirre, N. L., Cherrington, J. M., Lamy, P. D., Bischofberger, N., Pedersen, N. C., Marthas, M. L. (1999). Early Short-Term 9-[2-(R)-(Phosphonomethoxy)Propyl]Adenine Treatment Favorably Alters the Subsequent Disease Course in Simian Immunodeficiency Virus-Infected Newborn Rhesus Macaques. J. Virol. 73: 2947-2955 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»